Immunocore (IMCR) vs Inhibrx Biosciences (INBX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Immunocore is the larger company by market cap ($1.51 billion vs $1.37 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMCR | INBX |
|---|---|---|
| Share price | $29.41 | $93.36 |
| Market cap | $1.51B | $1.37B |
| 1-day change | -0.47% | -0.05% |
| YTD return | -15.27% | — |
| 1-year return | -14.06% | — |
| 5-year return | -22.61% | — |
| EPS (TTM) | $-0.36 | $-8.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.72 | $155.29 |
| 52-week low | $27.56 | $28.16 |
| Distance from 52-week high | -27.77% | -39.88% |
| Average volume | 449.06K | 296.25K |
| Shares outstanding | 51.50M | 14.72M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
IMCR vs INBX FAQ
Which is bigger, Immunocore or Inhibrx Biosciences?
Immunocore (IMCR) is larger, with a market capitalization of $1.51B compared with $1.37B for Inhibrx Biosciences (INBX).
Are Immunocore and Inhibrx Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.